Press coverage about Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) has been trending positive on Tuesday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kitov Pharmaceuticals Holdings earned a news impact score of 0.26 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.6093081192531 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) traded down $0.07 during trading hours on Tuesday, reaching $2.07. 90,400 shares of the company were exchanged, compared to its average volume of 243,927. Kitov Pharmaceuticals Holdings has a 1 year low of $1.27 and a 1 year high of $3.82.
Kitov Pharmaceuticals Holdings Company Profile
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
Receive News & Ratings for Kitov Pharmaceuticals Holdings Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals Holdings Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.